Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral salbutamol for cystic fibrosis with residual CFTR function
NL-OMON43663Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of salbutamol in cystic fibrosis (CF), sponsored by University Medical Center Utrecht. Primary endpoint: Pulmonary function. Planned start Jul 2015; status: not yet recruiting.
02
Drugs
salbutamol
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON43663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43663.